Grifols doesn't grimace when it comes to working with blood. The company provides products and services through three primary divisions: bioscience, diagnostic, and hospital. The bioscience division processes plasma from Grifols' collection centers into therapeutic derivative products such as coagulation factors and trauma products. Its diagnostic division sells testing instruments and reagents for laboratories, including blood bags, separators, incubators, and refrigerators. Grifols provides equipment, software, nutritional products, and IV preparations for hospitals and pharmacies through its hospital division. The firm serves as a holding company for the US operations of Spain-based Grifols, S.A.
Grifols has manufacturing sites in Clayton, North Carolina; Los Angeles California; and Melville, New York.
The company operates some 147 plasma collection centers around the US through its Biomat USA, PlasmaCare, and Plasma Collection Centers subsidiaries. The blood is then processed by fractionation facilities of PlasmaCare and then turned into therapeutic products by derivatives maker Grifols Biologicals. Product marketing and distribution functions are handled by the Grifols USA unit.
Grifols' revenues increased by 81% in 2011 thanks to its parent's acquisition of Talecris Biotherapeutics and related expansion of company's operations, an increase in sales volumes and revenues in its bioscience division.
Net income decreased by 56% in 2011 due to an increase in expenses related to the acquisition of Talecris. Operating expenses, depreciation and amortization of fixed assets, and amortization of intangible assets all increased a result of the Talecris purchase.
In 2012 Grifols signed a purchase agreement with the Canadian biopharmaceutical company for the acquisition of its three plasma donation centers located in the US. The deal will allow the company to conduct sophisticated viral testing and quality control analyses that help to ensure the safety of the plasma collected at all of its US plasma donation centers.
In 2011 parent Grifols, S.A. made a bold move towards expanding its operations in North America when it purchased plasma processor Talecris in a $4 billion deal. Talecris is a vertical provider of plasma collection, processing, and derivative production; the purchase doubled the size of Grifols' operations and bumped it into the top tier of plasma product makers.
The company has also undertaken a number of construction projects in effort to keep pace with its growing businesses. In addition to opening new plasma collection centers, the company is investing about $150 million to build new purification and sterile filling areas at its Los Angeles facilities. The LA projects are expected to be finished in 2013. Grifols also completed a new analytical laboratory in San Marcos, Texas, in 2012 near its existing lab in Austin. The expanded lab capacity allows the company to handle the growing amount of plasma samples needing to be analyzed and will reduce the company's dependence on a single facility.
Grifols is a subsidary of Grifols, S.A. – less